mGPS was the strongest significant prognostic biomarker in patients with metastatic renal cell carcinoma treated with nivolumab. This simple classification could be useful in clinical practice.
Carmelo Urdangarin AltunaCarmelo Urdangarin Altuna
Luis Sierra ZavalaJesús Ma Corral RecondoJesús Mª Corral RecondoUniversidad de Deusto
Ma Carmen GallasteguiJorge Armando García VillarrealJosé Mª Pérez de VillarrealInstituto de Economía Aplicada
Alberto Jiménez de AberasturiAlberto Jiménez de Aberasturi
Juan Carlos Landeta Basterretxea